Lung Cancer

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Sarah B. Goldberg, MD, MPH, discusses the combination of immunotherapy and targeted therapy for the treatment of patients with oncogene-driven lung cancer.

Treatment with afatinib (Gilotrif) followed by osimertinib (Tagrisso) led to a median overall survival of 41.3 months and a 2-year OS rate of 80% in patients with EGFR T790M-positive non–small cell lung cancer in a real-world setting.

As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies.

Alice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).

Konstantinos Arnaoutakis, MD, discusses pivotal updates in stage III disease, immunotherapy combinations in advanced non–small cell lung cancer, and advances in EGFR- and ALK-mutated lung cancer.

Matthew Steliga, MD, discusses key surgical updates in lung cancer and the shifting role of surgery with the emergence of novel therapies.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses new developments in RET-rearranged non–small cell lung cancer.

Heather A. Wakelee, MD, professor of medicine (oncology), Stanford University Medical Center, discusses osimertinib and its role in treating patients with EGFR-mutant non–small cell lung cancer.

With the arrival of immunotherapy to the small cell lung cancer armamentarium, combination approaches with targeted therapies are now in the pipeline to stimulate further clinical activity, such as adding PARP or CHK1 inhibitors.